MK 6913

Drug Profile

MK 6913

Alternative Names: MK-6913

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Karo Bio; Merck & Co
  • Class
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Female genital diseases
  • Discontinued Vasomotor symptoms

Most Recent Events

  • 31 Jul 2013 No development reported - Phase-I for Gynaecological disorders (unspecified route)
  • 30 Sep 2012 Merck and Karo Bio terminate their collaboration on estrogen receptors
  • 04 Apr 2012 Phase-I clinical trials in Female genital diseases (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top